Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome

Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome

1. Clinical Objective : To improve the growth of these children
2. Genetic objective : A study of the genetics of the syndrome

Inclusion Criteria:

• Children and adolescents with Noonan's syndrome with a height < -2 SD and no progressive cardiopathy

Exclusion Criteria:

• Age < 3 years
• Height ≥ -2 SD

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.